UK-based biotechnology company
Engitix plans to use the funds for preclinical development across its pipeline in solid tumors and fibrosis, and to expand its platform, it said in a statement Thursday. The company develops drugs targeting the extracellular matrix, known as ECM, which surrounds and supports cells and tissues in the body.
Michael Platt
Source: Bloomberg
Platt, the co-founder and chief executive officer of